News

Virginia Catalyst announces Grant Round 16 awarded projects!

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it has awarded $3.18 million in grants to four life and bioscience projects in the Commonwealth of Virginia. These grants, which will be met with significant matching funds from partner companies, were awarded through Grant Round 16.

“Powerful collaborations between Virginia’s research universities and industry is resulting in major breakthroughs in medical diagnostics, devices, and drug discovery” said Mike Grisham, CEO of Virginia Catalyst. “It’s also generating significant

Through this 16th round of funding, Virginia Catalyst has awarded 65 grants totaling nearly $33 million, resulting in over $50 million in matching funds and over $600 million in follow-on funding to date.

Grant Round 16 awarded projects:

Project:  Readmission Risk Assessment through Physiological and Behavioral Health Monitoring using

VitalStream Wireless Platform

  • Company: Caretaker Medical (Charlottesville, VA)
  • University collaborators: University of Virginia and Virginia Tech
  • Funding amount: $800,000

Project:  Optimization and Commercialization of PRECYSE as a Novel Quality Control Solution for Next Generation Sequencing

  • Company: Evizia, Inc. (Charlottesville, VA)
  • Funding amount: $800,000
  • University collaborators: Virginia Commonwealth University and University of Virginia

Project:  Developing an exercise-mimetic to treat diabetes

  • Company: MGMedicine, Inc. (Charlottesville, VA)
  • University collaborators: University of Virginia and Virginia Tech
  • Funding amount: $780,000

Project:  First-in-Class Bifunctional Cytokine to Target Tissue Resident Tregs for the Treatment of Idiopathic Nephropathy and other Autoimmune Diseases

  • Company: SlateBio, Inc. (Charlottesville, VA)
  • University collaborators: University of Virginia and Virginia Commonwealth University
  • Funding amount: $800,000

 

Recent News

11/18/2026

GeneDx Announces Leadership Transition

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that its Board of Directors has appointed Everett Cunningham as Chief Executive Officer and a member of the Board, effective on or before December 15, 2026. Mr. Cunningham succeeds Katherine Stueland, who has announced that …

11/17/2026

LifeNet Health Announced that Rony Thomas has Resigned

LifeNet Health announced that Rony Thomas has resigned as President and Chief Executive Officer and as a member of its Board of Directors, effective November 13, 2026. Mr. Thomas led LifeNet Health since 2004. During his tenure, the organization grew into a global leader in organ and tissue procurement and regenerative medicine. “On behalf of …

11/10/2026

Luminoah Raises $25 Million Series B to Expand Access to Its FDA-Cleared Enteral Feeding System

Luminoah, a medical technology company modernizing enteral nutrition, today announced a $25 million Series B financing led by Sandbox Clinical Ventures, with participation from the Blue Venture Fund, GV (Google Ventures), Sands Capital, Texas Medical Center Venture Fund, the CU Healthcare Innovation Fund, the American Gastroenterological Association GI Opportunity Fund, and existing investors. The Series …